These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32487607)

  • 21. Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin.
    Engle DB; Belisle JA; Gubbels JA; Petrie SE; Hutson PR; Kushner DM; Patankar MS
    Gynecol Oncol; 2009 Mar; 112(3):631-6. PubMed ID: 19263582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines.
    Engblom P; Rantanen V; Kulmala J; Helenius H; Grènman S
    Br J Cancer; 1999 Jan; 79(2):286-92. PubMed ID: 9888470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
    Smith JA; Ngo H; Martin MC; Wolf JK
    Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
    Jia L; Zhou J; Zhao H; Jin H; Lv M; Zhao N; Zheng Z; Lu Y; Ming Y; Yu Y
    Oncol Rep; 2017 Oct; 38(4):2464-2470. PubMed ID: 28791374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vitamin D3 stimulates embryonic stem cells but inhibits migration and growth of ovarian cancer and teratocarcinoma cell lines.
    Abdelbaset-Ismail A; Pedziwiatr D; Suszyńska E; Sluczanowska-Glabowska S; Schneider G; Kakar SS; Ratajczak MZ
    J Ovarian Res; 2016 Apr; 9():26. PubMed ID: 27091127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel-carboplatin chemotherapy does not cause encephalopathy in patients with ovarian cancer: a prospective EEG mapping study in 28 patients.
    Mayerhofer K; Bodner K; Saletu B; Bodner-Adler B; Anderer P; Hefler L; Schindl M; Kaider A; Leodolter S; Kainz C
    Anticancer Res; 2001; 21(1B):803-8. PubMed ID: 11299847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
    Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells.
    van Haaften C; Boot A; Corver WE; van Eendenburg JD; Trimbos BJ; van Wezel T
    J Exp Clin Cancer Res; 2015 Apr; 34(1):38. PubMed ID: 25907439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined chemotherapy with paclitaxel and carboplatin for mucinous cystadenocarcinoma of the ovary during pregnancy.
    Doi D; Boh Y; Konishi H; Asakura H; Takeshita T
    Arch Gynecol Obstet; 2009 Oct; 280(4):633-6. PubMed ID: 19205713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
    Joerger M; Huitema AD; Richel DJ; Dittrich C; Pavlidis N; Briasoulis E; Vermorken JB; Strocchi E; Martoni A; Sorio R; Sleeboom HP; Izquierdo MA; Jodrell DI; Calvert H; Boddy AV; Hollema H; Féty R; Van der Vijgh WJ; Hempel G; Chatelut E; Karlsson M; Wilkins J; Tranchand B; Schrijvers AH; Twelves C; Beijnen JH; Schellens JH
    Clin Cancer Res; 2007 Nov; 13(21):6410-8. PubMed ID: 17975154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients.
    Battaglia A; Buzzonetti A; Fossati M; Scambia G; Fattorossi A; Madiyalakan MR; Mahnke YD; Nicodemus C
    Cancer Immunol Immunother; 2020 Mar; 69(3):383-397. PubMed ID: 31897661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acetaminophen modulations of chemotherapy efficacy in MDAH 2774 human endometrioid ovarian cancer cells in vitro.
    Bilir A; Altinoz MA; Attar E; Erkan M; Aydiner A
    Neoplasma; 2002; 49(1):38-42. PubMed ID: 12044058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro.
    Uruski P; Sepetowska A; Konieczna C; Pakuła M; Wyrwa M; Tussupkaliyev A; Tykarski A; Mikuła-Pietrasik J; Książek K
    Cell Mol Biol Lett; 2021 Oct; 26(1):44. PubMed ID: 34674640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.
    Brotto L; Brundage M; Hoskins P; Vergote I; Cervantes A; Casado HA; Poveda A; Eisenhauer E; Tu D; ; ;
    Support Care Cancer; 2016 Mar; 24(3):1241-9. PubMed ID: 26304156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer.
    Waltmire CN; Alberts DS; Dorr RT
    Anticancer Drugs; 2001 Aug; 12(7):595-602. PubMed ID: 11487716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
    Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
    BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
    Joly F; Ray-Coquard I; Fabbro M; Donoghoe M; Boman K; Sugimoto A; Vaughan M; Reinthaller A; Vergote I; Ferrandina G; Dell'Anna T; Huober J; Pujade-Lauraine E
    Gynecol Oncol; 2011 Aug; 122(2):226-32. PubMed ID: 21575983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.
    Mayerhofer K; Bodner-Adler B; Bodner K; Leodolter S; Kainz C
    Anticancer Res; 2000; 20(5C):4047-50. PubMed ID: 11268499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.